The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 05, 2014

Filed:

Mar. 23, 2010
Applicants:

John A. Bender, Middletown, CT (US);

Piyasena Hewawasam, Middletown, CT (US);

John F. Kadow, Wallingford, CT (US);

Omar D. Lopez, Wallingford, CT (US);

Nicholas A. Meanwell, East Hampton, CT (US);

Van N. Nguyen, Meriden, CT (US);

Jeffrey Lee Romine, Meriden, CT (US);

Lawrence B. Snyder, Killingworth, CT (US);

Denis R. St. Laurent, Newington, CT (US);

Gan Wang, Wallingford, CT (US);

Ningning Xu, Wallingford, CT (US);

Makonen Belema, North Haven, CT (US);

Inventors:

John A. Bender, Middletown, CT (US);

Piyasena Hewawasam, Middletown, CT (US);

John F. Kadow, Wallingford, CT (US);

Omar D. Lopez, Wallingford, CT (US);

Nicholas A. Meanwell, East Hampton, CT (US);

Van N. Nguyen, Meriden, CT (US);

Jeffrey Lee Romine, Meriden, CT (US);

Lawrence B. Snyder, Killingworth, CT (US);

Denis R. St. Laurent, Newington, CT (US);

Gan Wang, Wallingford, CT (US);

Ningning Xu, Wallingford, CT (US);

Makonen Belema, North Haven, CT (US);

Assignee:

Bristol-Myers Squibb Company, Princeton, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4178 (2006.01); A61K 31/4184 (2006.01); A61P 31/14 (2006.01); C07D 403/14 (2006.01); C07D 405/14 (2006.01);
U.S. Cl.
CPC ...
Abstract

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.


Find Patent Forward Citations

Loading…